Find Academic Supervisors

Amar U. KishanView profile

Professor

• Translational Research
• Clinical Outcomes Research
• Advanced Radiation Technologies
• +5 more

Amar U. Kishan, MD , a tenure Professor at the David Geffen School of Medicine, UCLA , serves as Executive Vice Chair for the Department of Radiation Oncology and as Chief of the Genitourinary Service since 2019. His clinical expertise focuses on radiation treatment of prostate and bladder cancers , with pioneering work in stereotactic body radiation therapy (SBRT) and image-guided radiotherapy . Dr. Kishan graduated magna cum laude from Harvard Medical School after dual BA degrees at UC Berkeley in Molecular and Cell Biology and Public Health, followed by residency at UCLA and internship at Scripps Mercy Hospital . Education : Harvard Medical School (MD, 2012), UC Berkeley (BA in Molecular/Cell Biology & Public Health) Awards : Leonard Tow Humanism in Medicine (2021), UCLA Exceptional Physician (2024), Super Doctors® Rising Stars (2020-2024) Dr. Kishan leads translational research connecting radiation oncology with genitourinary cancer biology. His 310+ publications in journals like JAMA , Lancet Oncology , and European Urology emphasize radiation technology innovations , including MRI-guided SBRT and adaptive radiation therapy. Key trials he spearheads include ILLUSION (CT-guided SBRT) and HEATWAVE (apalutamide + SBRT). Major funding sources include National Institutes of Health , Department of Defense , and Prostate Cancer Foundation . His work has redefined prostate cancer treatment paradigms , demonstrating that high-dose radiation can match surgery in aggression cases, while multi-modal approaches improve survival rates. Dr. Kishan also contributes to re-irradiation protocols and radioresistance proteogenomics , advancing precision oncology. Key Grants : NIH, DoD, PCF, ASTRO Clinical Trials : ILLUSION, HEATWAVE, PET imaging-based radiation targeting

David GillattView profile

Professor

• Urological Oncology
• Robotic Surgery
• Prostate Cancer Diagnosis
• +5 more

Professor David Gillatt is a leading urological oncologist and robotic surgeon at Macquarie University, specializing in prostate and bladder cancer treatments. He holds roles as Director of Medical and Surgical Services at MQ Health, Head of Urology Clinical Discipline, and Professor of Urological Oncology and Robotics. With over 25 years of experience, he has performed over 2,000 major resections and pioneered the Enhance Recovery program for cystectomy, a globally recognized innovation. His clinical expertise includes robotic surgery training programs and advanced pelvic cancer surgery. Education and Qualifications: Gillatt holds a Bachelor of Surgery and Medicine from the University of Manchester (1980), Fellowships from the Royal College of Surgeons of England (1993), Edinburgh (1984), and the Royal Australasian College of Surgeons (2015). Research Focus: His work spans clinical trials and basic science, including biomarker discovery for prostate cancer (e.g., IGFs and volatile diagnostics) and the impact of ketamine abuse on bladder function. He led the Bristol Chief Investigator role for the national PROTECT study and established the Prostate Cancer Care and Research Centre in the UK. Projects and Collaborations: Key projects include robotic surgery training methodologies, high-dose vitamin D trials for prostate cancer (Pros-D), and molecular imaging advancements for bladder cancer using upconversion nanoparticles. Awards and Recognition: His fellowships (FRCS, FRACS) and contributions to global urological advancements highlight his expertise. He is recognized for strengthening Macquarie’s multidisciplinary prostate cancer care model. Labs and Teams: He leads surgical and research teams at Macquarie University Hospital, collaborating on bioreactor technologies and cancer radioimmunotherapy initiatives.

• Prostate Cancer
• Radiation Therapy
• Imaging Techniques
• +3 more

Shafak Al-Uwini is a researcher at the Faculty of Medical Sciences, University of Groningen, with a focus on prostate cancer and radiation therapy. They are affiliated with the Personalized Cancer Treatment (PCT) and Innovative Clinical Studies and Long-term Treatment Consequences in Cancer (InClinS) research groups. Research Interests: Shafak Al-Uwini specializes in prostate cancer management, radiation therapy, imaging techniques (e.g., PSMA-PET, CT), and treatment planning. Their work addresses clinical decision-making, salvage radiotherapy, and automated radiotherapy planning. Publication Trends: Recent articles emphasize the role of PSMA-PET in prostate cancer management, synthetic CT generation for radiotherapy, and multidisciplinary approaches to metastatic disease. Topics include imaging, automation, and clinical outcomes. Professional Activities: They have delivered invited presentations (e.g., Prostaat radiotherapie - de rol van protonen, 2018) and collaborated internationally (e.g., Technische Universität Dresden, 2018).

• Terahertz Imaging
• Medical Physics
• Computational Oncology
• +2 more

Pouyan Rezapoor is a Doctoral Researcher affiliated with Aalto University's Department of Electronics and Nanoengineering. His research focuses on terahertz imaging systems, medical physics, and computational modeling for cancer treatment. Research areas: Terahertz imaging, MRI-guided radiotherapy, and electromagnetic wave propagation Key collaborations: Zachary Taylor Group, Dan Ruan, and international researchers in biomedical engineering Current work examines radiation toxicity prediction in prostate cancer patients and optical system design for THz imaging. Recent publications analyze telecentric lens systems, cross-polarization effects, and computational methods to address feature correlation in clinical data.

• Cancer Epidemiology
• Breast Cancer
• Reproductive Epidemiology
• +3 more

Anna Johansson is an Assistant Professor at the Karolinska Institutet , leading research in cancer epidemiology and biostatistics at the Department of Medical Epidemiology and Biostatistics . She serves as a Docent and group leader, with affiliations at Karolinska University Hospital, Capio St Göran Hospital, and Uppsala University Hospital. Research Interests: Her work spans Cancer epidemiology with focus on breast cancer Reproductive factors and cancer risk Socioeconomic inequalities in healthcare Applied biostatistics and register-based methods Nordic cross-country collaborations Recent Article Trends show emphases on Nordic cancer survival comparisons Pregnancy-associated cancer outcomes Stage-specific mortality analysis Impact of healthcare disruptions Statistical methods for registry data Fertility preservation in oncology Scientific Awards Senior Investigator Award, Swedish Cancer Society Teaching & Mentorship includes survival analysis, epidemiological designs, and data management workshops within the Karolinska Doctoral Programme. She supervises PhD students in cancer and reproductive epidemiology. Collaborative Networks extend to the Nordic Cancer Union, Cancer Registry of Norway, and clinical research teams across Sweden and the Nordic region.

• Medical Physics
• Radiation Therapy
• Medical Imaging
• +7 more

Andrew Fielding is an Associate Professor in the School of Chemistry & Physics at Queensland University of Technology (QUT), Faculty of Science. His research and teaching focus on medical physics, particularly in radiation therapy, medical imaging, and Monte Carlo dosimetry techniques. He is the Course Coordinator for the Graduate Diploma and Master of Applied Science in Medical Physics programs at QUT. He holds a PhD in Physics from the University of Portsmouth and a B.Sc. (Hons) from the University of Surrey. He completed postdoctoral research at the Institute of Cancer Research / Royal Marsden Hospital and the University of Liverpool before joining QUT in 2004. His academic progression includes Lecturer (2004–2008), Senior Lecturer (2008–2022), and Associate Professor (2023–present). His research interests lie in medical imaging, radiation therapy, image-guided radiotherapy, Monte Carlo techniques for dosimetry, and radiation oncology physics. He emphasizes translating research into clinical practice to improve cancer care. His recent publications reflect a strong focus on Monte Carlo simulations, small-field dosimetry, preclinical irradiation, and the integration of AI and simulation in radiotherapy education and treatment verification. His scientific achievements are recognized through professional memberships including Fellow of the Institute of Physics (FInstP), Chartered Physicist (CPhys), and Member of the Australasian College of Physical Scientists and Engineers in Medicine (MACPSEM). Fellow of the Institute of Physics (FInstP) Chartered Physicist (CPhys) Member of the Australasian College of Physical Scientists and Engineers in Medicine (MACPSEM) Andrew Fielding actively supervises PhD and research master’s students in areas such as Monte Carlo dosimetry, tumor motion tracking, and radiotherapy optimization. He has secured competitive research grants, including Australian Competitive Grants for projects on tumor motion monitoring and in-vivo dosimetry verification. His teaching philosophy emphasizes authentic, clinically aligned learning using simulation, virtual reality, and real-world applications. He leads or teaches several core medical physics units, including Radiation Physics, Radiotherapy, Medical Imaging Science, and Research Methodology. He is involved in developing and evaluating innovative tools such as 3D volumetric outlining systems and immersive simulation environments for radiotherapy training. His work bridges physics, clinical application, and education, contributing significantly to the advancement of medical physics both in research and pedagogy.

• Radiation Oncology
• Therapeutic Radiology
• Cancer Treatment
• +8 more

Dr. Patrick Oh serves as an Assistant Professor of Therapeutic Radiology at Yale School of Medicine, practicing as a radiation oncologist at Yale Cancer Center and Smilow Cancer Hospital. He specializes in treating thoracic and genitourinary cancers, as well as hematologic, cutaneous, and metastatic malignancies with an emphasis on individualized, holistic patient care to optimize both disease outcomes and quality of life. His educational background includes: BS from Duke University MD from Stony Brook University School of Medicine Preliminary Medicine Intern at NYU Langone Hospital-Long Island Resident Physician in Radiation Oncology at Yale New Haven Hospital (served as Chief Resident) Gamma Knife Cranial Radiosurgery Certification from Cleveland Clinic Dr. Oh's research focuses on reducing radiation-induced toxicities, particularly cardiopulmonary effects, and expanding the role of radiation therapy across various cancer types. His clinical expertise encompasses advanced radiotherapy techniques including stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT/VMAT), and image-guided radiation therapy (IGRT). Professional recognition includes: RSNA Roentgen Resident Research Award (awarded June 7, 2025) Dr. Oh is dedicated to medical education, actively mentoring residents and medical students with emphasis on communication skills and patient-centered care. He maintains active professional memberships including the American Society for Therapeutic Radiology (2021-present), where he serves on the Board of the Korean American Society for Therapeutic Radiation Oncology (2024-present), and the American Society of Clinical Oncology (2018-present). He treats both adult and pediatric patients and accepts new appointments through Yale Medicine.

Abhijit PatelView profile

Associate Professor

• Liquid Biopsy
• Circulating Tumor DNA
• Cancer Detection
• +6 more

Abhijit Patel, MD, PhD is an Associate Professor of Therapeutic Radiology at Yale School of Medicine and serves as the Medical Director of the Lawrence & Memorial Cancer Care Center in Waterford. His work focuses on developing innovative liquid biopsy approaches for cancer detection and monitoring, with particular emphasis on circulating tumor DNA analysis. Dr. Patel received his medical education at Yale University School of Medicine (MD, 2003) and completed his PhD in Molecular Biophysics and Biochemistry from Yale University Graduate School (2002). His training includes an internship at Memorial Sloan-Kettering Cancer Center (2004), residency in Radiation Oncology at Harvard Medical School (2008), and postdoctoral research at the Howard Hughes Medical Institute, Massachusetts General Hospital (2008). His research program centers on developing ultrasensitive diagnostic tools to measure trace amounts of circulating tumor DNA molecules through analysis of genomic and epigenomic signatures. Dr. Patel's work addresses key challenges in liquid biopsy technology, including assay development for circulating tumor DNA detection, high-throughput RNA profiling, and clinical applications for early cancer detection, treatment response assessment, and monitoring treatment resistance. His research draws upon expertise from clinical oncology, molecular biology, chemistry, computer science, and microfluidics. Analysis of Dr. Patel's recent publications reveals a strong focus on advancing liquid biopsy technologies for cancer detection and monitoring. His work spans technical innovations in DNA sequencing and analysis, clinical validation studies across multiple cancer types (particularly lung cancer), and collaborative efforts through the Liquid Biopsy Consortium to address challenges in early cancer detection. His research consistently aims to bridge the gap between molecular diagnostics and clinical oncology practice. Lungevity Foundation Early Detection Award (2015) Tina's Wish Foundation Research Award (2015) ASTRO Junior Faculty Career Research Training Award (2011) Brozman Foundation Fellowship (2011) American Cancer Society Institutional Research Grant (2010) Dr. Patel serves as a sub-investigator on multiple clinical trials focused on cancer detection and treatment, including studies on adjuvant radiotherapy for head and neck cancer, mechanisms of treatment resistance in lung cancer, and peripheral blood profiling for lung cancer screening. He leads the Patel Lab at Yale, which collaborates extensively with scientists and clinicians across disciplines to advance liquid biopsy technologies for clinical implementation.

Septimiu (Tim) E. SalcudeanView profile

Professor

• Medical Robotics
• Image-Guided Interventions
• Medical Image Analysis
• +5 more

Septimiu (Tim) E. Salcudean is a Professor in the Department of Electrical and Computer Engineering at the University of British Columbia (UBC), holding both the Laszlo Chair in Biomedical Engineering and a Canada Research Chair. He earned his BEng and MEng from McGill University and his PhD from UC Berkeley in Electrical Engineering. From 1986 to 1989, he was a Research Staff Member at IBM T.J. Watson Research Center's robotics group before joining UBC. Education: BEng (McGill University, 1979) MEng (McGill University, 1981) PhD (University of California at Berkeley, 1986) Dr. Salcudean's research focuses on Medical Robotics , Image-Guided Interventions , and Elastography applications . He develops systems for robot-assisted surgery with da Vinci integration and ultrasound vibro-elastography for tissue parameter identification. His work spans prostate brachytherapy guidance , needle insertion simulation , and haptic interfaces for virtual environments. His research projects include Medical robotics with da Vinci system integration Ultrasound vibro-elastography for tissue analysis Needle insertion simulation in deformable tissue Prostate brachytherapy treatment planning His publications demonstrate expertise in Robotics and control systems Medical imaging and segmentation Teleoperation and haptics Scientific Awards: NSERC Synergy Award (2009) IEEE Fellowship (2004) UBC Killam Research Prize (2004) PRECARN Research Excellence Award (2008) Best Paper Awards (2004, 2003, 1999) As Technical/Editorial Board member of IEEE Transactions on Robotics and steering committee member at IPCAI , he contributes to academic leadership. He has supervised numerous graduate students in projects ranging from medical ultrasound to needle steering systems , with funding from NSERC, CIHR, and NIH. The Robotics and Control Laboratory at UBC, which he co-leads, houses advanced equipment including 5-DOF haptic interfaces, ultrasound machines, and motion simulators for medical and industrial applications.

Andrew Z. WangView profile

Professor

• Cancer Research
• Nanotechnology
• Biomedical Engineering
• +2 more

Andrew Z. Wang, M.D., is a tenured Professor and holds the A. Kenneth Pye Professorship in Cancer Research at the University of Texas Southwestern. He serves as Vice Chair for Translational Research and Commercialization in the Department of Radiation Oncology, having joined UTSW in August 2021. Previously, he held faculty positions at the University of North Carolina, where he rose from Assistant to Tenured Professor. Dr. Wang's research integrates biomedical engineering with oncology to develop innovative cancer diagnostics and therapeutics. His work focuses on: Nanotechnology-enabled drug delivery systems Cancer immunotherapy and vaccine development Biomaterial applications in oncology Liquid biopsy technologies for treatment monitoring Radiotherapy-enhancing strategies His 128+ publications demonstrate consistent focus on translational nanomedicine, with recent works advancing combination therapies (chemoradiation-immunotherapy), 3D-printed medical devices, and machine learning applications in oncology. Clinical publications emphasize optimizing radiation techniques for genitourinary/gastrointestinal cancers. Major scientific recognitions include: Fellow of the American Association for the Advancement of Science (AAAS) Fellow of the American Institute for Medical and Biological Engineering (AIMBE) Fellow of the American Society for Clinical Investigation (ASCI) A. Kenneth Pye Professorship in Cancer Research Dr. Wang leads a prolific research program generating 38 patents and founding three biotechnology startups. Clinically, he specializes in advanced radiation techniques (IMRT, SBRT, brachytherapy) for genitourinary and gastrointestinal malignancies.

Sameer NathView profile

Associate Professor

• Radiation Oncology
• Prostate Cancer
• Lung Cancer
• +3 more

Sameer Nath, MD, is an Associate Professor in the Department of Radiation Oncology at the University of Colorado Anschutz Medical Campus School of Medicine. He holds leadership roles as Vice Chair of Clinical Affairs, Clinical Practice Director at Anschutz Medical Campus, and Medical Director of Radiation Oncology at Highlands Ranch Hospital. Dr. Nath is board-certified in Radiation Oncology and practices at UCHealth Radiation Oncology and Rocky Mountain Gamma Knife Center. MD: University of California, San Diego School of Medicine (2010) Internship: University of California, San Diego (2011) Residency: Yale-New Haven Medical Center, Chief Resident in Radiation Oncology (2015) His research focuses on radiation therapy applications for prostate and lung cancers, brain metastases management, and immunotherapy-radiation combinations. He has pioneered work in stereotactic body radiation therapy (SBRT), tumor hypoxia, radiation pneumonitis prevention, and medical imaging innovations for treatment planning. Recent publications examine oligoprogressive prostate cancer management, radiation oncology nurse education, and deep learning applications in patient positioning. Dr. Nath's 15 most recent publications (2024-2017) demonstrate expertise in prostate cancer (4 articles), lung cancer (4 articles), brain metastases (4 articles), and medical imaging/education (3 articles). Key research themes include SBRT optimization, immunotherapy response monitoring, and radiation toxicity management. American Society of Radiation Oncology (ASTRO) Member Practice locations: UCHealth Radiation Oncology - Anschutz Medical Campus (Aurora, CO) and Rocky Mountain Gamma Knife Center - Anschutz Medical Campus (Aurora, CO) Hospital affiliations: UCHealth Highlands Ranch Hospital and University of Colorado Hospital

• Exercise Oncology
• Cancer Rehabilitation
• Prostate Cancer Treatment
• +3 more

Professor Daniel Galvão is a leading academic in exercise oncology at Edith Cowan University (ECU), Australia. He serves as Director of the Exercise Medicine Research Institute and holds a Professorship in Exercise and Sports Science within the School of Medical and Health Sciences. His research focuses on optimizing exercise interventions to mitigate treatment-related toxicities and improve outcomes for cancer patients, particularly those with prostate cancer. Galvão has secured over $26 million in grants from bodies like the NHMRC, Movember Foundation, and Cancer Australia, supporting multidisciplinary trials and survivorship programs. Education: PhD (Edith Cowan University, 2006), Master of Applied Science in Clinical Exercise Science (University of Queensland, 2003). His career includes roles as Co-Director of ECU’s Health and Wellness Institute and Fellowships with the American College of Sports Medicine and Exercise and Sports Science Australia. Research emphasizes exercise as medicine in oncology, with over 200 peer-reviewed publications. Key contributions include guidelines for exercise in cancer patients and landmark trials like ERADICATE (prostate cancer radiotherapy adjuncts) and TelEX (weight management for prostate cancer). Notable awards include the 2021 Asian Pacific Prostate Cancer Conference Best Poster, 2014 Edith Cowan Vice-Chancellor’s Award, and 2007 ESSA PhD Medal. He chairs national research committees and reviews for high-impact journals like Journal of Clinical Oncology and European Urology . Current initiatives include nationwide exercise programs for prostate cancer survivors and translational research on myokine mechanisms in cancer suppression. His work bridges clinical practice with evidence-based interventions to enhance patient quality of life and survival outcomes.

• Head and Neck Cancer
• Radiation Oncology
• HPV-associated Oropharyngeal Cancer
• +7 more

Dr. Jason Chan is an Associate Professor in the Department of Radiation Oncology at the University of California, San Francisco (UCSF) School of Medicine. His clinical practice focuses on the treatment of head and neck, skull base, cutaneous, and thoracic malignancies, offering advanced techniques including Cyberknife radiosurgery and high-dose-rate brachytherapy for both initial and repeat radiotherapy. Dr. Chan received his medical degree from Brown University and completed his Internal Medicine internship at Kaiser Permanente San Francisco followed by a residency in Radiation Oncology at UCSF. His academic journey has positioned him as a prominent researcher in head and neck oncology, with particular expertise in HPV-associated oropharyngeal cancer, nasopharyngeal cancer, lung cancer, thyroid cancer, and cutaneous malignancies. His research spans multiple domains including radiation therapy optimization, AI applications in radiation oncology, cancer outcomes research, and translational studies. Dr. Chan's work frequently addresses critical questions in treatment de-escalation for HPV-positive cancers, reirradiation techniques, and health disparities in cancer outcomes. Recent publications demonstrate his leadership in investigating swallowing function outcomes, dosimetric analysis of brachytherapy, and the impact of socioeconomic factors on nasopharyngeal carcinoma outcomes. Dr. Chan actively participates in numerous clinical trials and translational studies, particularly in head and neck and lung cancers. His collaborative approach is evident in his extensive co-authorship network with colleagues at UCSF and other institutions. His work bridges clinical practice with technological innovation, especially in the application of artificial intelligence to radiation therapy planning and delivery. Dr. Chan's research portfolio reflects a commitment to improving both the precision and accessibility of cancer care while addressing significant clinical challenges in radiation oncology.

Arnold I. ChinView profile

Professor

• Urologic Oncology
• Renal Transplantation
• Cancer Stem Cell Research
• +3 more

Dr. Arnold I. Chin is a Professor of Urology and Medical Director of Urology-Westwood at the David Geffen School of Medicine at UCLA. He completed both his MD and PhD at UCLA and completed his urology residency training there as well. His clinical expertise spans urologic oncology and renal transplantation, with specialization in open, laparoscopic, and robotic-assisted surgeries for bladder, kidney, and prostate cancer patients. Dr. Chin's educational background includes: MD, UCLA School of Medicine, 2003 PhD, UCLA, 2002 Internship in Surgery, UCLA School of Medicine, 2004 Residency in Urology, UCLA School of Medicine, 2009 Dr. Chin's research focuses on understanding cancer differentiation and its interplay with the tumor microenvironment. His laboratory investigates molecular mechanisms in programming tumor-infiltrating lymphocytes and mechanisms controlling development and differentiation of cancer stem cells. His work aims to develop novel therapeutic targets, immune-based platforms, and stem cell-directed therapies against cancer. He is affiliated with the Broad Stem Cell Research Center, Tumor Immunology Program Area, and Genitourinary Oncology Program Area of the Jonsson Comprehensive Cancer Center. His recent research has centered on bladder cancer, prostate cancer, renal cell carcinoma, and neuroendocrine carcinomas, with emphasis on tumor microenvironment, immunotherapy approaches, and molecular targets for cancer treatment. Dr. Chin has received several prestigious awards: Super Doctors® Southern California, 2022-2025 Super Doctors® Southern California Rising Stars 2018 STOP Cancer Research Career Development Award 2010 American Association of Cancer Research Career Development Award for Translational Cancer Research 2010 Dr. Chin is actively involved in mentoring students and research fellows in his laboratory, guiding them in cutting-edge cancer research. His work has been supported by various grants from organizations including STOP Cancer and the American Association of Cancer Research. He is also involved in clinical trials related to urologic cancers. Dr. Chin leads a translational research laboratory focused on tumor microenvironment in prostate and bladder cancer, using a combination of animal models, human reconstitution systems, and primary tumor and hematopoietic cells. His team is investigating molecular mechanisms in programming tumor-infiltrating lymphocytes and the development and differentiation of cancer stem cells.

Dong-Hyun KimView profile

Professor

• Therapeutic Carriers
• Nanotechnology
• Cancer Therapy
• +9 more

Dong-Hyun Kim, PhD, is a Professor at the Feinberg School of Medicine and McCormick School of Engineering at Northwestern University. His research focuses on developing therapeutic micro/nanoparticles for cancer treatment, including drug delivery, hyperthermia, immunotherapy, and molecular imaging. He collaborates with clinicians, biologists, and imaging professionals to translate multifunctional carriers into clinical applications. Education: PhD: Yonsei University College of Medicine, Korea (2006) Postdoctoral Fellow: University of Alabama, Chemical & Biological Engineering (2008) Postdoctoral Fellow: Argonne National Laboratory, Materials Science Division (2011) Research Interests: Therapeutic carriers for cancer treatment (e.g., nanoparticles, microspheres) Interventional oncology and targeted drug delivery Immunotherapy integration with nanotechnology Diagnostic imaging (MRI, CT, ultrasound) for treatment monitoring Translational research bridging lab and clinical applications Key Trends in Publications: Recent work emphasizes CRISPR-mediated genome editing, ferroptosis-inducing nanoparticles, cryo-immunotherapy, and radiomics for tumor assessment. Articles highlight synergy between nanotechnology and immunotherapy, with a focus on liver, prostate, and pancreatic cancers. Affiliations: Northwestern University Clinical and Translational Sciences Institute (NUCATS) Robert H. Lurie Comprehensive Cancer Center Labs/Teams: Active in multidisciplinary teams developing nanomedicine and interventional oncology therapies, leveraging Northwestern’s clinical and engineering resources.